ArticleHemaSphere2022
The EHA Research Roadmap: Malignant Lymphoid Diseases.
Abstract read
In one paragraph
Article in HemaSphere, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
54 authors.
Martin DreylingDepartment of Medicine III, LMU Hospital, Munich, Germany.
Marc AndréUniversité Catholique de Louvain, CHU UcL Namur, Yvoir, Belgium.
Nicola GökbugetDepartment of Medicine II, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
Hervé TillyINSERM U1245, Department of Hematology, Centre Henri Becquerel and Université de Rouen, France.
Mats JerkemanSkåne University and Lund University, Lund, Sweden.
John GribbenBarts Cancer Institute, Queen Mary University of London, United Kingdom.
Andrés FerreriLymphoma Unit, Department of Onco-hematology, IRCCS San Raffaele Scientific Institute, Milano, Italy.
Pierre MorelService Hematologie Clinique Therapie Cellulaire, CHU Amiens Picardie, Amiens, France.
Stephan StilgenbauerComprehensive Cancer Center Ulm (CCCU), Sektion CLL Klinik für Innere Medizin III, Universität Ulm, Germany.
Christopher FoxSchool of Medicine, University of Nottingham, United Kingdom.
José Maria RiberaClinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Badalona, Spain.
Sonja ZweegmanAmsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, the Netherlands.
Igor AurerUniversity Hospital Centre Zagreb and Medical School, University of Zagreb, Croatia.
Csaba BödörHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Birgit BurkhardtExperimentelle und Translationale päd. Hämatologie u Onkologie, Leitung der Bereiche Lymphome und Stammzelltransplantation, Universitätsklinikum Münster (UKM), Klinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie und Onkologie, Munich, Germany.
Christian BuskeInstitute of Experimental Cancer Research, CCC Ulm, University Hospital Ulm, Germany.
Maria Dollores CaballeroClinical and Transplant Unit, University Hospital of Salamanca, Spain.
Elias CampoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Bjoern ChapuyDepartment of Hematology, Oncology and Tumor Immunology, Charité, University Medical Center Berlin, Campus Benjamin Franklin, Berlin, Germany.
Andrew DaviesSouthampton NCRI/UK Experimental Cancer Medicines Centre, Faculty of Medicine, University of Southampton, United Kingdom.
Laurence de LevalDepartment of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.
Jeanette DoorduijnDepartment of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Massimo FedericoCittà di Lecce Hospital, GVM Care & Research, Lecce, Italy.
Philippe GaulardDépartement de Pathologie, Hôpital Henri Mondor, AP-HP, Créteil, France.
Francesca GayClinical Trial Unit, Division of Hematology 1, AOU Città Della Salute e Della Scienza, University of Torino, Italy.
Paolo GhiaUniversità Vita Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy.
Kirsten GrønbækDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Hartmut GoldschmidtUniversity Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Marie-Jose KerstenDepartment of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam and LYMMCARE, Amsterdam, the Netherlands.
Barbara KiesewetterDepartment of Medicine I, Division of Oncology, Medical University of Vienna, Austria.
Judith Landman-ParkerPediatric Hematology Oncology, Sorbonne Université APHP/hôpital A Trousseau, Paris, France.
Steven Le GouillService d'Hématologie, Clinique du Centre Hospitalier Universitaire (CHU) de Nantes, France.
Georg LenzMedical Department A for Hematology, Oncology and Pneumology, University Hospital Münster, Germany.
Sirpa LeppäUniversity of Helsinki and Helsinki University Hospital Comprehensive Cancer Centre, Helsinki, Finland.
Armando Lopez-GuillermoDepartment of Hematology, Hospital Clínic de Barcelona, Spain.
Elizabeth MacintyreOnco-hematology, Université de Paris and Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, France.
Maria Victoria Mateos MantegaComplejo Asistencial Universitario de Salamanca, IBSAL, CIC, Universidad de Salamanca, Ciberonc, Salamanca, Spain.
Philippe MoreauHematology Department, University Hospital Hotel-Dieu, Nantes, France.
Carol MorenoHospital de la Santa Creu I Sant Pau, Autonomous University of Barcelona, Spain.
Bertrand NadelAix Marseille Univ, CNRS, INSERM, CIML, Marseille, France.
Jessica OkosunCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, United Kingdom.
Roger OwenSt James's Institute of Oncology, Leeds, United Kingdom.
Sarka PospisilovaDepartment of Internal Medicine-Hematology and Oncology and Department of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University and University Hospital Brno, Czech Republic.
Christiane PottKlinisch-experimentelle Hämatologie, Medizinische Klinik II, Hämatologie und Internistische Onkologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Germany.
Tadeusz RobakMedical University of Lodz, Poland.
Michelle SpinaDivision of Medical Oncology and Immune-related Tumors, National Cancer Institute, Aviano, Italy.
Kostas StamatopoulosInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Jan StaryDepartment of Pediatric Hematology and Oncology 2nd Faculty of Medicine, Charles University Prague University Hospital, Prague, Czech Republic.
Karin TarteImmunology and Cell Therapy Lab at Rennes University Hospital, Rennes, France.
Allessandra TedeschiDepartment of Hematology, Niguarda Hospital Milano, Italy.
Catherine ThieblemontDepartment of Hemato-Oncology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Ralf Ulrich TrappeDepartment of Internal Medicine II: Haematology and Oncology, DIAKO Hospital Bremen, Germany.
Lorenz H TrümperHematology and Medical Oncology, University Medicine Goettingen, Germany.
Gilles SallesLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.